Modafinil Reference

Educational, not medical advice reference for Modafinil: Nootropic; regulatory status, evidence posture, source review, and schedule notes. Also…

Plain English

What it is
Modafinil (brand name Provigil) is a prescription medicine that the FDA approved to help adults stay awake. It is approved for excessive sleepiness caused by narcolepsy, shift-work sleep disorder, and obstructive sleep apnea (a breathing problem during sleep).
What people use it for
Outside its approved sleep uses, it is one of the most talked-about off-label 'smart drugs' that people use to feel focused and alert during long stretches of work. That focus use is not what the FDA approved it for.
What the science shows
The evidence is strong for the approved sleepiness conditions. For sharpening thinking in healthy people the studies are small, and this remains an unapproved use.
The catch
Modafinil is a Schedule IV controlled substance, so it is regulated and available only with a prescription. Its label also warns of rare but serious skin reactions, including Stevens-Johnson syndrome, that have led to hospitalization.

Reference summary

Modafinil is label-verified for the listed sleep-medicine indications. Off-label cognitive-enhancement use is studied in small trials; off-label use is outside the approved indication.

Regulatory and posture

Categories
Nootropic
Aliases
Provigil, Modalert, Modvigil
Evidence posture
human - FDA-approved Schedule IV controlled substance for narcolepsy / shift-work sleep disorder / obstructive sleep apnea. Off-label cognitive-enhancement use is outside the approved indication. Possession without a prescription is a federal offense.
Regulatory status
FDA-approved prescription medication (Provigil). Indicated for narcolepsy, shift-work sleep disorder, and obstructive sleep apnea (as adjunct). Schedule IV controlled substance under the federal Controlled Substances Act.
Content review status
label verified

Selected public sources

For research and educational purposes only. Not medical advice.